Hepatocellular carcinoma (HCC) is the most common primary liver cancer. HCC is the fourth cause of cancer-related mortality and the fifth most common cancer in the world. The prognosis and survival of patients depend mainly on the cancer stage at time of diagnosis. Earlier detection of the disease has seen improvement in treatment and disease-free survival over the last several decades. Currently, the only curable treatment for HCC is tumor resection or transplantation. These measures are strictly successful only if caught during early-stage HCC.
Research has identified multiple molecular pathways involved in HCC on genetic, epigenetic, and proteomic levels. There has been a lot of research into designing drugs to specifically target these molecular pathways affected in patients, and thus contributing to personalized medical treatment. There is abundant bioinformatic research to document the extensive molecular pathways involved as well as drug docking techniques used to assess drug candidates for treating those affected pathways. These bioinformatic techniques result in identifying candidates suitable for further analysis in tissue and animal models and human trials.
The aim of this Research Topic is to build on the current research on the topic of personalized medicine in HCC and to detail future promises it can offer. We encourage the submission of review articles and original research that would validate the pathways for HCC and the drugs that could affect those pathways. We welcome bioinformatics and laboratory studies that present data on the molecular pathogenesis of HCC. Drug-docking techniques are also welcomed including confirmation and validation that molecular docking offers new viable drug therapy options, which could be used in clinical practice in the near future. We will also assess human trial data on personalized medicine treatment of HCC.
The scope of the Research Topic is to study the molecular pathways of HCC and the drugs that affect those pathways. Themes include, but are not limited to, the following:
- Genetic, epigenetic, proteomic molecular pathways for HCC.
- Drug-docking research for those pathways.
- Validation of the drugs that could affect the molecular pathways through laboratory, tissue, animal and human trials.
- Clinical trials on HCC drug therapy in various phases (I-IV) will be also welcomed to present their preliminary or final data.
- Analysis of drug action at different stages of cancer, e.g. Sorafenib is used drug in terminal HCC only.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. HCC is the fourth cause of cancer-related mortality and the fifth most common cancer in the world. The prognosis and survival of patients depend mainly on the cancer stage at time of diagnosis. Earlier detection of the disease has seen improvement in treatment and disease-free survival over the last several decades. Currently, the only curable treatment for HCC is tumor resection or transplantation. These measures are strictly successful only if caught during early-stage HCC.
Research has identified multiple molecular pathways involved in HCC on genetic, epigenetic, and proteomic levels. There has been a lot of research into designing drugs to specifically target these molecular pathways affected in patients, and thus contributing to personalized medical treatment. There is abundant bioinformatic research to document the extensive molecular pathways involved as well as drug docking techniques used to assess drug candidates for treating those affected pathways. These bioinformatic techniques result in identifying candidates suitable for further analysis in tissue and animal models and human trials.
The aim of this Research Topic is to build on the current research on the topic of personalized medicine in HCC and to detail future promises it can offer. We encourage the submission of review articles and original research that would validate the pathways for HCC and the drugs that could affect those pathways. We welcome bioinformatics and laboratory studies that present data on the molecular pathogenesis of HCC. Drug-docking techniques are also welcomed including confirmation and validation that molecular docking offers new viable drug therapy options, which could be used in clinical practice in the near future. We will also assess human trial data on personalized medicine treatment of HCC.
The scope of the Research Topic is to study the molecular pathways of HCC and the drugs that affect those pathways. Themes include, but are not limited to, the following:
- Genetic, epigenetic, proteomic molecular pathways for HCC.
- Drug-docking research for those pathways.
- Validation of the drugs that could affect the molecular pathways through laboratory, tissue, animal and human trials.
- Clinical trials on HCC drug therapy in various phases (I-IV) will be also welcomed to present their preliminary or final data.
- Analysis of drug action at different stages of cancer, e.g. Sorafenib is used drug in terminal HCC only.
